By reducing those intrusive thoughts, GLP-1 medications may help some patients feel more in control around food and less mentally consumed by eating decisions
Dulaglutide in the era of tirzepatide and semaglutide: reaffirming its role in contemporary cardiometabolic care
[1] [2] The FDA label also includes important warnings about potential serious adverse events including thyroid C-cell tumors (boxed warning), pancreatitis, gallbladder disease, acute kidney injury, and hypersensitivity reactions including anaphylaxis and angioedema
On average, patients may lose around 2% to 4% of their body weight within the first month of using semaglutide, although individual results vary
When were engaging in different patterns of behavior that are contrary to what weve been doing for a year, five years, several decades, were building new neural pathways
A 2023 meta-analysis in JAMA Internal Medicine found a possible association with medullary thyroid carcinoma specifically, but the absolute risk remained very low